CMU Research Validates Improved Clinical Trial Processes
Opportunities to reduce content on consent forms by over 80% and using video formats can improve patient comprehension and engagement
Dublin, Ireland â ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today welcomed the results of ICON-supported research at Carnegie Mellon University (CMU) which validate a shorter, simple approach to patient consent processes. The results, which were recently published in
Medical Decision Making
journal, show that patient consent forms could be shortened by up to 86% without losing critical understanding or sacrificing the content required by ethics boards. The research also found greater patient engagement when using a shorter paper form or when using a video format, compared with more traditional, paper-based approaches. Academic researchers at CMU conducted a number of studies evaluating patient-centric and patient-designed informed consent formats. In the first study, 118 asthma patients examined sections of a standard informed consent document for an asthma trial and then selected and ranked the information they deemed critical to their decision making. In the second study, 83 asthma patients were randomly assigned to review either a full informed consent document; a shortened document, based on patient preferences from the first study; or a video that presented patient consent information in an animated format. The video was developed by ICON, using its Firecrest suite of multi-media solutions. In the first study, patients identified a fraction of the content on a typical informed consent form as relevant to their deciding whether to participate in a trial. Their preferences led to a significantly (86%) shorter consent form, with greater emphasis on aspects that directly affected them (including trial procedures, potential side effects and benefits) and less attention to aspects that mattered less to them (e.g. privacy assurances, procedural information for clinical staff). In the second study, participants who received the shortened paper form and video format absorbed as much information as participants receiving the long form, and described themselves as more engaged. Those receiving the video format rated themselves significantly higher scores on physician trust. Commenting on the results of the CMU research, Dr. Lars-Olof Eriksson, EVP Site and Patient Recruitment, said: “Informed consent materials are very often long, complicated and too technical which is why we commissioned CMU to examine how a simpler, more patient-centric approach would affect patients’ understanding, confidence and trust. Through this research, patients have made their information needs and preferences very clear. We have already incorporated the CMU research findings into our Firecrest eConsent and Patient Portal solutions and we remain committed to developing further innovative solutions that drive better patient recruitment and engagement in clinical trials.” ICON’s
Firecrest Patient Portal
is the patient’s gateway to clinical trials and has been specifically designed to enhance patients’ understanding of treatment before consenting to participate in a trial. Patients using the Patient Portal can find active trials, complete pre-screening questionnaires and watch educational videos in the comfort of their own homes, before choosing a convenient study location. The Patient Portal also includes a patient visit-by-visit guide, which informs patients about what to expect during site visits.
About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 89 locations in 37 countries and has approximately 12,200 employees. Further information is available at
www.iconplc.com
.
Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps
March 4th 2025Phase III WAYPOINT trial shows Tezspire (tezepelumab) significantly reduces nasal polyp size and congestion severity in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, while also decreasing the need for surgery and systemic glucocorticoids.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
